Risk Benefit Data from the International Duodenal Jejunal Bypass Liner (DJBL) Registry
REJ RYDER1, A ESCALONA2, R LOPEZ-GONZALEZ3, C LAZZARA3, J PUJOL-GEBELLI3, J STEIN4, T BATTELINO5, JP TEARE6, A RUBAN6, M HALUZIK7, L MUNRO8, H FRYDENBERG8, JJ.
DTN-UK Webinar: Update and discussion of current position of the HCL rollout
Thursday 11th September 2025, 17:00 - 18:00
Join the Diabetes Technology Network UK (DTN-UK) for a discussion of the current state of hybrid closed loop (HCL) rollout and any issues arising from this.
Together we will explore:
ABCD Conference 2025 - Programme
Please note this draft programme is subject to change
ABCD DTN Principles for CGM Choice in HCL systems: Clinical Need, Cost-Effectiveness, and Patient Safety
The use of HCL may enable provision of different CGM options. We agree that, provided accuracy standards are met, cost-effectiveness needs to be considered, and therefore encourage choice based on clinical need, with selection of the lowest cost device that meets an individual’s specific requirements. It is sensible that the lowest cost option should be the default choice, but where this does not meet an individual’s requirements an alternative should be available.
